New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 15, 2014
09:25 EDTAZN, AZN, BMY, BMY, CLDX, CLDX, MRK, MRK, IMUC, IMUC, NWBO, NWBO, RHHBY, RHHBYLeerink's pharma and biotech analysts hold an analyst/industry conference call
Pharmaceuticals Analyst Fernandez and Biotech Analyst Liang, along with Key Opinion Leader Dr. David Reardon, discuss new developments in Glioblastoma (GBM) on an Analyst/Industry conference call. Relevant companies AZN, BMY, CLDX, MRK, IMUC, NWBO and RHHBY may be discussed on the Analyst/Industry conference call to be held on April 15 at 10 am.
News For AZN;BMY;CLDX;MRK;IMUC;NWBO;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
August 24, 2015
07:08 EDTBMYBristol-Myers upgraded to Neutral from Underweight at Piper Jaffray
Subscribe for More Information
05:13 EDTAZNAstraZeneca to collaborate with Peregrine on cancer immunotherapy clinical trial
Subscribe for More Information
August 23, 2015
12:35 EDTAZN, RHHBY, MRK, BMYBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
15:26 EDTNWBONorthwest Biotherapeutics confirms Phase 3 trial of DCVax-L is ongoing
Northwest Biotherapeutics confirmed that its Phase III trial of DCVax-L for newly diagnosed glioblastoma multiforme is ongoing and the patients enrolled in the trial are continuing to be treated per the protocol. Over 300 patients have been recruited for the trial. The total anticipated enrollment is 348 patients. The only change in status of the trial is that new screening of patient candidates for the trial has been temporarily suspended while the company submits certain information from the trial for regulatory review. Such screening involves the initial evaluation of patient candidates to determine whether they meet eligibility criteria for the trial. Some blogs and social media comments have noted that the EudraCT trials database in Europe states that there is a "Temporary Halt" of the trial in Germany. In actuality, the trial status in Germany is that the trial is ongoing as noted above, and the company has only undertaken a temporary suspension of new screening. The company has sought to have the EudraCT listing corrected, but the database includes only certain pre-specified categories and there is no category that corresponds to a temporary suspension of new screening only, while a trial is ongoing. The company is in the process of preparing the trial information for regulatory review and anticipates submission within the next couple of weeks.
12:49 EDTNWBONorthwest Bio stops screening new patients in DCVax-L study, Reuters reports
Subscribe for More Information
09:38 EDTRHHBYUBS global healthcare analysts hold an analyst/industry conference call
Subscribe for More Information
09:13 EDTNWBOOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Accuray (ARAY), up 12.7%... Brocade (BRCD), up 6%... salesforce.com (CRM), up 3.5%. DOWN AFTER EARNINGS: Intuit (INTU), down 6.7%... Deere (DE), down 5.4%... Nordson (NDSN), down 4.4%. ALSO LOWER: GigOptix (GIG), down 20% after 9.22M share Spot Secondary priced at $1.70... VirnetX Holding (VHC), down 19.8% after filing to sell 35M shares of common stock... Northwest Biotherapeutics (NWBO), down 8.7% after TheStreet's Adam Feuerstein reports, via Twitter, that CVax Phase 3 study has been temporarily halted in Germany.
08:49 EDTNWBONorthwest Phase 3 study halted in Germany TheStreet's Feuerstein says
The European Union Clinical Trials Register says Northwest Biotherapeutics' DCVax Phase 3 study has been "temporarily halted" in Germany, TheStreet's Adam Feuerstein reports via Twitter. Shares of Northwest are down 63c to $8.25 in pre-market trading.
06:08 EDTIMUCImmunoCellular says ICT-107 advancing to final stage of development
Subscribe for More Information
05:44 EDTMRKStocks with implied volatility movement; DIS MRK
Subscribe for More Information
August 20, 2015
11:33 EDTMRK, AZNLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
09:23 EDTAZNAdvaxis, MedImmune begin enrollment in axalimogene filolisbac Phase I/II study
Subscribe for More Information
08:38 EDTMRKMerck says to present new analyses from IMPROVE-IT study
Subscribe for More Information
06:01 EDTBMYBristol-Myers announces Canadian approval of Daklinza
Subscribe for More Information
August 19, 2015
05:46 EDTBMYStocks with implied volatility movement; ESRX BMY
Subscribe for More Information
August 18, 2015
12:13 EDTMRKMerck recalls Temodar, Temozolomide bottles with cracked caps
Subscribe for More Information
08:03 EDTMRKMerck says FDA accepts sBLA for Keytruda
Subscribe for More Information
07:22 EDTBMYBristol-Myers combo data could push shares above $70, says JPMorgan
JPMorgan analyst Chris Schott says the risk/reward for shares of Bristol-Myers Squibb looks "very attractive" ahead of the World Conference on Lung Cancer, which begins September 6. Data at the conference supportive of an Opdivo/Yervoy combo would represent a clear catalyst for the shares, Schott tells investors in a research note. Bristol is "already extremely well-positioned" in the advanced non-small cell lung cancer market, and data suggesting that the company has addressed toxicity concerns with the combo could push the stock above $70, Schott argues. Bristol closed yesterday up 39c to $63.47. The analyst sees limited downside to stock even with disappointing results at the World Conference on Lung Cancer. He reiterates an Overweight rating on Bristol with a $75 price target.
August 17, 2015
08:43 EDTBMYBristol-Myers sells Ixempra to R-PHARM, terms not disclosed
R-PHARM announces the acquisition of Ixempra from Bristol-Myers Squibb. Ixempra received marketing approval from the FDA in 2007 and in 18 other markets globally. Ixempra is indicated as monotherapy or in combination with capecitabine for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine. With the acquisition, R-PHARM has launched its U.S. commercial operations, and it is now responsible for all activities surrounding Ixempra's manufacture, distribution, sales, and reimbursement. Financial terms were not disclosed.
05:14 EDTRHHBYGenentech reports atezolizumab pivotal Phase II study met primary endpoint
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use